Sponsored Links

XenoPort to drop multiple sclerosis drug after trial failure

Mon May 20, 2013 6:42am EDT

May 20 (Reuters) - XenoPort Inc said it will stop developing its experimental multiple sclerosis treatment after data from a late-stage trial showed the drug did not improve patients' condition significantly compared with a placebo.

The company said it will shut down all activities related to the drug, arbaclofen placarbil, and planned to provide an update on the impact of the expected savings.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.